CD161

• Description:

  CD161 is a potent, selective and orally bioavailable bromodomain and extra-terminal (BET) bromodomain inhibitor with an IC50s of 28.2 nM and 7.2 nM for BRD4 BD1 and BRD4 BD2, respectively. CD161 has good anticancer activity[1].

• UNSPSC:

  12352005

• Target:

  Epigenetic Reader Domain

• Type:

  Reference compound

• Related Pathways:

  Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cd161.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CC1=NC (C2=CC=NC3=CC=CC=C23) =C4C (NC5=C4C=C (OC) C (C6=C (C) ON=C6C) =C5) =N1

• Molecular Formula:

  C26H21N5O2

• Molecular Weight:

  435.48

• References & Citations:

  [1]Zhao Y, et al. Structure-Based Discovery of 4- (6-Methoxy-2-methyl-4- (quinolin-4-yl) -9H-pyrimido[4,5-b]indol-7-yl) -3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor. J Med Chem. 2017 May 11;60 (9) :3887-3901.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  1627716-22-6